Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity

v3.19.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2019
Equity [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]
Note 5 — Stockholders’ Equity
 
Stock Purchase Transaction
 
On February 8, 2019, InvaGen acquired 5,833,333 shares of the Company’s common stock at $6.00 per share for net proceeds of $31.5 million after deducting commission fees and other offering costs, representing a 33.3% stake in the Company’s capital stock on a fully diluted basis.
 
Equity Incentive Plan
 
The Company has in effect the 2015 Incentive Plan (“2015 Incentive Plan”). The 2015 Incentive Plan was adopted in January 2015 by our stockholders. Under the 2015 Incentive Plan, the compensation committee of the Company’s board of directors is authorized to grant stock-based awards to directors, officers, employees and consultants. The plan authorizes grants to issue up to 2,000,000 shares of authorized but unissued common stock and expires 10 years from adoption and limits the term of each option to no more than 10 years from the date of grant.
 
Restricted Stock Units and Restricted Stock Awards
 
The following table summarizes restricted stock unit and award activity for the three months ended March 31, 2019:
 
 
 
Number of Units
and Awards
 
 
Weighted
Average Grant
Date Fair Value
 
Unvested balance at December 31, 2018
 
 
1,104,643
 
 
$
4.45
 
Granted
 
 
50,000
 
 
$
5.75
 
Vested
 
 
(89,326
)
 
$
5.75
 
Unvested balance at March 31, 2019
 
 
1,065,317
 
 
$
4.41
 
 
For the three months ended March 31, 2019 and 2018, stock-based compensation expenses associated with the amortization of restricted stock units and restricted stock awards for employees and non-employees were approximately $0.8 million and $0.4 million, respectively.
 
At March 31, 2019, the Company had unrecognized stock-based compensation expense related to restricted stock units and restricted stock awards of $2.3 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.7 years.
 
Stock Options
 
The following table summarizes stock option award activity for the three months ended March 31, 2019:
 
 
 
Stock Options
 
 
Weighted
Average Exercise 
Price
 
 
Weighted Average
Remaining
Contractual Life
(in years)
 
Outstanding, December 31, 2018
 
 
20,000
 
 
$
6.29
 
 
 
3.63
 
Cancelled/forfeited
 
 
(20,000
)
 
 
6.29
 
 
 
-
 
Outstanding, March 31, 2019
 
 
-
 
 
$
-
 
 
 
-
 
 
Stock Warrants
 
The following table summarizes the warrant activity for the three months ended March 31, 2019:
 
 
 
Warrants
 
 
Weighted
Average Exercise 
Price
 
 
Aggregate 
Intrinsic Value
(in thousands)
 
Outstanding, December 31, 2018
 
 
102,597
 
 
$
0.0976
 
 
$
544
 
Exercised
 
 
(56,075
)
 
$
0.0001
 
 
 
-
 
Outstanding, March 31, 2019
 
 
46,522
 
 
$
0.2151
 
 
$
211